Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hologic (NASDAQ: HOLX), SeaSpine Holdings (NASDAQ: SPNE) and Regeneron (NASDAQ: REGN).
Hologic (NASDAQ: HOLX)
BTIG analyst Sean Lavin maintained a Buy rating on Hologic (NASDAQ: HOLX) on May 2 and set a price target of $44. The company’s shares closed on Friday at $37.93.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.0% and a 63.2% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.
Currently, the analyst consensus on Hologic is Moderate Buy and the average price target is $44.09, representing a 16.2% upside.
In a report issued on April 17, Goldman Sachs also maintained a Buy rating on the stock with a $43 price target.
Find more picks by Best Performing Analysts >>
SeaSpine Holdings (NASDAQ: SPNE)
In a report issued on May 4, Ryan Zimmerman from BTIG maintained a Buy rating on SeaSpine Holdings (NASDAQ: SPNE), with a price target of $17. The company’s shares closed on Friday at $10.75.
Zimmerman observed:
“in the New Year; Maintain Buy, $17 PT Our thesis is unchanged as SPNE put up solid results in 1Q18. Recall that SPNE has been transitioning the US spinal hardware business from legacy products to newer products that should (and are) growing at a faster pace, namely Mariner and Shoreline. While it has taken a few quarters, SPNE now has ~45% (up from ~24% in 1Q17) of its US spinal implant revenue coming from newer products. Combined with a growing exclusive distributor base, results came in slightly above expectations at $33.2M (+4.0%) relative to BTIG/Consensus of $32.5M/$32.7M respectively. In addition, orthobiologics continues to grow in the MSD from the strength of the portfolio, +5.2% WW, +4.9% US. SPNE is launching multiple products in both categories through FY18 (including a lateral system, Regatta, in 3Q18) while also developing instrumentation that works with navigation access. Collectively, the business continues its positive progression, the portfolio continues to build, and growth should increase to the MSD to HSD in 2H18. While macro spine dynamics remain soft, SPNE is a share taker (even if it is at a smaller scale than others). We maintain our Buy rating and $17 PT.”
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 31.1% and a 61.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and Globus Medical.
Currently, the analyst consensus on SeaSpine Holdings is Moderate Buy and the average price target is $16, representing a 48.8% upside.
In a report issued on May 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $15 price target.
Regeneron (NASDAQ: REGN)
BTIG analyst Dane Leone maintained a Hold rating on Regeneron (NASDAQ: REGN) on May 3. The company’s shares closed on Friday at $291.25, close to its 52-week low of $287.55.
Leone observed:
“On Thursday before-market open, REGN reported 1Q18 financial results and updated the business outlook for 2018. While we appreciate CEO Len Schleifer’s honest disdain for the investment community, his stance is unlikely to help bolster confidence with longer-term shareholders within the current investment environment. We had downgraded the stock several months ago as pipeline efforts proved disappointing, and currently, we find no reason to become more optimistic. We remain NEUTRAL.”
According to TipRanks.com, Leone is a 5-star analyst with an average return of 17.6% and a 69.2% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Vertex Pharmaceuticals, and Blueprint Medicines.
Currently, the analyst consensus on Regeneron is Hold and the average price target is $395.54, representing a 35.8% upside.
In a report issued on May 1, Guggenheim also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
